Pure Global

Stanford and University of Illinois Chicago ACE-D Study - Trial NCT06408246

Access comprehensive clinical trial information for NCT06408246 through Pure Global AI's free database. This Phase 2 trial is sponsored by Stanford University and is currently Not yet recruiting. The study focuses on Depression. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06408246
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06408246
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Stanford and University of Illinois Chicago ACE-D Study
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial

Study Focus

Depression

Guanfacine

Interventional

drug

Sponsor & Location

Stanford University

Palo Alto,Chicago, United States of America

Timeline & Enrollment

Phase 2

Feb 01, 2026

Feb 01, 2029

160 participants

Primary Outcome

Remission of depressive symptoms

Summary

The purpose of this study is to understand how a psychotropic medication called guanfacine
 affects brain network functioning in humans, and how this function interacts with cognitive
 impairments in people experiencing depressive symptoms.

ICD-10 Classifications

Depressive episode
Other depressive episodes
Recurrent depressive disorder
Recurrent depressive disorder, unspecified
Post-schizophrenic depression

Data Source

ClinicalTrials.gov

NCT06408246

Non-Device Trial